Polzastobart (Anti-LILRB2 / ILT4 / CD85d), 1mg

Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities.